Although it is postulated that SGLT2 inhibitors exert a diuretic effect that removes interstitial fluid to reduce the risk of HF, this effect is transient and modest and cannot account for the long-term outcome in clinical trials. The gene discussed is SLC5A2; the disease is hydrops fetalis.